retatrutide nejm 2023 obesity trial ly3437943 Early data for demonstrates exceptional weight loss results, reaching approximately 21% placebo-adjusted weight loss by week 48. This performance significantly exceeds all other leading medications currently under retatrutide peptide | peptidesskin

These have been pulled together in a useful meta-analysis by Monami and colleagues, published in 2010

Clear documentation of medical necessity and patient education about realistic weight loss expectations strengthens prescribing decisions

Wegovy is specifically approved by the FDA for chronic weight management

2023: Ozempic and Wegovy are listed on FDAs Durg Shortages list

There are a few rare additional side effects: Severe allergic reactions have been reported with GLP-1 agonists

[DOI] [PMC free article] [PubMed] [Google Scholar] 173.Nielsen LB, Ploug KB, Swift P, rskov C, Jansen-Olesen I, Chiarelli F, Holst JJ, Hougaard P, Prksen S, Holl R, de Beaufort C, Gammeltoft S, Rorsman P, Mortensen HB, Hansen L